Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Top U.S. trade negotiator meets Pfizer, AstraZeneca execs on COVID-19 IP waiver

Stock MarketsApr 26, 2021 09:35PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: U.S. Senate panel holds hearing on Biden's trade nominee 2/2

By Andrea Shalal

WASHINGTON (Reuters) - U.S. Trade Representative Katherine Tai on Monday met virtually with top executives of drugmakers Pfizer (NYSE:PFE) and AstraZeneca (NASDAQ:AZN) PLC to discuss a proposed waiver of certain intellectual property rights in response to the COVID-19 pandemic.

Members of the World Trade Organization are due to discuss a proposal by India and South Africa to waive certain provisions of the WTO's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) on April 30, but the United States and a few other big countries have blocked such a move.

Democratic lawmakers, civil society groups, and 60 former heads of state and 100 Nobel Prize winners have urged President Joe Biden to back the waiver. White House Press Secretary Jen Psaki on Monday said she had no updates on the issue.

Tai's meetings with the Pfizer and AstraZeneca executives reflect her intense engagement on the issue, and follow similar meetings with advocacy groups, industry executives and others.

Earlier this month, Tai told a WTO meeting the gaping divide between developed and developing countries' access to medicines was "completely unacceptable" and industry needed to make sacrifices in times of crisis.

In her discussion with Pfizer Chief Executive Dr. Albert Bourla, Tai emphasized her commitment to working with other members of the WTO on a global response to the crisis, her office said in a statement.

That included "the role of developing countries in any solution that addresses critical gaps in global production and distribution of vaccines," USTR said.

Tai also discussed the issue with Dr. Ruud Dobber, head of U.S. business at AstraZeneca, as well as the White House's decision to share up to 60 million doses of AstraZeneca's COVID-19 vaccine with countries in need.

USTR said Tai and Dobber discussed "increasing vaccine production, global health issues and the proposed waiver."

Top U.S. trade negotiator meets Pfizer, AstraZeneca execs on COVID-19 IP waiver
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (3)
Felipe Daniel
Felipe Daniel Apr 26, 2021 11:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Plannedemic is about profits and control.
danny Levine
danny Levine Apr 26, 2021 9:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
they won't. vaccines is all this covid drama about
Hunter Gassaway
Hunter Gassaway Apr 26, 2021 9:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Big Pharma needs their profits and nobody has ********to say it is true nor the spine to say help your fellow human being you are sharing this planet with. They can afford to do so.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email